1-(3-氯苯胺基)-4-苯基酞嗪
|
|
|
- CAS号:
- 78351-75-4
- 英文名:
- MY-5445
- 英文别名:
- MY-5445;MY 5445;MY5445;1-(3-CHLOROANILINO)-4-PHENYLPHTHALAZINE;1-(3-Chloroanilino)-4-phenylphthalazine >1-(3-CHLOROPHENYLAMINO)-4-PHENYLPHTHALAZINE;N-(3-chlorophenyl)-4-phenylphthalazin-1-amine;N-(3-Chlorophenyl)-4-phenyl-1-phthalazinamine;1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl-;aggregation,platelet,Inhibitor,anticancer,inhibit,MY5445,neuropathic,MY 5445,Phosphodiesterase (PDE),neuropathic pain,allodynia,MY-5445
- 中文名:
- 1-(3-氯苯胺基)-4-苯基酞嗪
- 中文别名:
- 化合物MY-5445;1-(3-氯苯胺基)-4-苯基酞嗪;N-(3-氯苯基)-4-苯基酞嗪-1-胺
- CBNumber:
- CB9739543
- 分子式:
- C20H14ClN3
- 分子量:
- 331.8
- MOL File:
- 78351-75-4.mol
|
|
|
1-(3-氯苯胺基)-4-苯基酞嗪化学性质
-
沸点:
-
539.7±50.0 °C(Predicted)
-
|
-
密度:
-
1.310±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at RT
-
|
-
溶解度:
-
DMF: 2 mg/ml; DMSO: 2 mg/ml; DMSO:PBS(pH 7.2) (1:2): 0.3 mg/ml
-
|
-
酸度系数(pKa):
-
4.91±0.30(Predicted)
-
|
-
形态:
-
Yellow solid.
-
|
-
颜色:
-
White to Light yellow
-
|
1-(3-氯苯胺基)-4-苯基酞嗪性质、用途与生产工艺
MY-5445 是一种特异性的 cGMP 磷酸二酯酶 PDE5 抑制剂，其 Ki 值为 1.3 μM。MY-5445 能抑制人血小板凝集。MY-5445 是一种 ABCG2 转运蛋白调节剂，具有抗增殖活性。
|
PDE5
1.3 μM (Ki)
|
PDE5
6.7 μM (IC
50
)
|
PDE4
37 μM (IC
50
)
|
MY-5445 inhibits human platelet aggregation by increasing cyclic GMP content and that it provides a useful probe for elucidating the role of cyclic GMP in platelet aggregation .
MY-5445 selectively reverses ABCG2-mediated multidrug resistance in ABCG2-overexpressing cells.
MY-5445 reverses ABCG2-mediated multidrug resistance (MDR) by potentiating the cytotoxicity of an ABCG2 substrate drug in ABCG2-overexpressing multidrug-resistant cancer cells, possibly by modulating the function and/or the protein expression of ABCG2.
MY-5445 (3 μM; 48 hours) substantially increases the topotecan-induced apoptosis in S1-M1-80 cell.
Apoptosis Analysis
|
Cell Line:
|
Human S1 colon cancer cells, S1-M1-80 cancer cells
|
|
Concentration:
|
3 μM
|
|
Incubation Time:
|
48 hours
|
|
Result:
|
Enhanced drug-induced apoptosis in ABCG2-overexpressing cancer cells.
|
MY-5445 (0.5-3 mg/kg; i.p.; twice a day; for 15 days) produces a significant relief of mechanical hypersensitivity.
|
Animal Model:
|
C57BL/6J male mice
|
|
Dosage:
|
0.5 mg/kg, 3 mg/kg
|
|
Administration:
|
Intraperitoneal injection, twice a day, for 15 days
|
|
Result:
|
Alleviated the cuff-induced allodynia.
|
1-(3-氯苯胺基)-4-苯基酞嗪
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | C2884 | 1-(3-氯苯胺基)-4-苯基酞嗪
1-(3-Chloroanilino)-4-phenylphthalazine | 78351-75-4 | 20mg | 280元 |
| 2024/04/30 | HY-100933 | MY-5445 | | 1 mg | 304元 |
78351-75-4, 1-(3-氯苯胺基)-4-苯基酞嗪 相关搜索:
- Cyclic Nucleotide related
- 药靶配体
- 哒嗪
- C20H14ClN3
- 化合物MY-5445
- N-(3-氯苯基)-4-苯基酞嗪-1-胺
- 1-(3-氯苯胺基)-4-苯基酞嗪
- 78351-75-4
- 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl-
- aggregation,platelet,Inhibitor,anticancer,inhibit,MY5445,neuropathic,MY 5445,Phosphodiesterase (PDE),neuropathic pain,allodynia,MY-5445
- 1-(3-Chloroanilino)-4-phenylphthalazine >
- MY 5445;MY5445
- N-(3-chlorophenyl)-4-phenylphthalazin-1-amine
- N-(3-Chlorophenyl)-4-phenyl-1-phthalazinamine
- 1-(3-CHLOROANILINO)-4-PHENYLPHTHALAZINE
- 1-(3-CHLOROPHENYLAMINO)-4-PHENYLPHTHALAZINE
- MY-5445